Pharmacie sans ordonnance livraison rapide 24h: acheter viagra en ligne en France.

Understanding ms related spasticity

Understanding MS related spasticity
FAST FACTS
• Multiple sclerosis (MS) is an incurable condition that affects approximately 100,000 people in the UK and is usually diagnosed between the ages of 20 • Damage occurs within the central nervous system (CNS - brain and spinal • Spasticity is a common symptom associated with MS,3 affecting most people • In a survey, 84% of people with MS reported symptoms of spasticity4 • Symptoms of spasticity include loss of mobility, painful spasms / cramps, • There are a number of medicinal therapies commonly used to treat spasticity, although not all are licensed for this purpose6 • Many have side effects which some people find difficult to tolerate at effective Background
• Multiple sclerosis (MS) is an incurable condition that affects approximately 100,000 people in the UK in which damage occurs within the central nervous system (CNS - brain and spinal cord).1 It is usually diagnosed between the ages of 20 and 40 years2 • Spasticity is a common symptom associated with MS3 and is a major contributor • Spasticity is caused by damage to the nerves in the CNS that carry messages instructing muscles how to move, resulting in an involuntary muscle over-activity • In a survey, 84% of people with MS reported symptoms of spasticity.4 Moderate, severe or total spasticity is reported in 34% of individuals.4 • Symptoms of spasticity include loss of mobility, painful spasms / cramps, stiffness and / or weakness of muscles.5 As a consequence an individual may have difficulty in walking, picking up objects, washing, dressing and other everyday activities involving movement.3 • In addition to causing a great deal of distress to the person with MS, mood, self- image and motivation can also be affected.7 Job code: UK.PH.SM.SAT.2010.051 Date of preparation: May 2010 Management and treatment of spasticity
• Spasticity is difficult to measure. A variety of scales and measures are used by doctors and physiotherapists to quantify the different aspects of the condition.7 • Treatments for spasticity range from physiotherapy and exercise programmes, to drug treatment, and surgery in the most severe cases.7 • There are a number of medicinal therapies available to treat MS-related spasticity. NICE guidance states that the first line of treatment should be baclofen or gabapentin, although gabapentin is not licensed for treating spasticity. Other medications may be used only if treatment with baclofen or gabapentin is unsuccessful or side effects are unmanageable.8 • Despite the range of treatment options, not all patients with MS spasticity can achieve adequate symptom relief. Also, at effective doses many existing oral drug treatments for MS spasticity have side effects which some people find difficult to tolerate.6 References
1. Multiple Sclerosis Society. About MS. Available at 2. NHS Choices. Multiple Sclerosis Introduction. Available at 3. Multiple Sclerosis Trust. Multiple Sclerosis Information for Health and Social Care http://www.mstrust.org.uk/downloads/ms_information_for_hps.pdf (Last accessed: 4. Rizzo MA, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Multiple Sclerosis 2004;10:589/595 5. Multiple Sclerosis Trust. Spasticity and Spasms factsheet. November 2009 6. Beard S, et al. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003;7(40) 7. Multiple Sclerosis International Federation. Spasticity in MS. MS in focus. Issue 12. 2008. Available at http://www.msif.org/docs/MSinFocusIssue12EN.pdf (Last accessed: 8. The National Institute of Clinical Excellence (NICE) Management of multiple sclerosis in primary and secondary care. NICE; London:2003 Job code: UK.PH.SM.SAT.2010.051 Date of preparation: May 2010

Source: http://www.gwpharm.net/uploads/msrelatedspasticitybackgrounder100510final.pdf

pico.sssup.it

J. Plant Physiol. 159. 1383 – 1386 (2002) Urban & Fischer Verlaghttp://www.urbanfischer.de/journals/jpp Short Communication Elicitors of defence responses repress a gibberellin signalling pathway in barley embryos Elena Loreti1, Daniela Bellincampi2, Christel Millet3, Amedeo Alpi3, Pierdomenico Perata4 *1 Istituto di Biologia e Biotecnologia Agraria, sezione di Pisa, Via del Borgh

What are the primary features of rls

WHAT ARE THE PRIMARY FEATURES OF RLS? • There is a strong urge to move your legs which you may not be able to resist. The urge is usually, but not always, accompanied by uncomfortable sensations. They may be described as tingling, creepy-crawly, itching, pulling, tugging or gnawing. • The urge to move and uncomfortable sensations begin or worsen when at rest- for example, while sitting

Copyright © 2010-2014 Sedative Dosing Pdf